Biochemical Genetics

Published on 16/03/2015 by admin

Filed under Basic Science

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 3412 times

CHAPTER 11 Biochemical Genetics

In this chapter, we consider single-gene biochemical or metabolic diseases, including mitochondrial disorders. The range of known disorders is vast, so only an overview is possible, but it is hoped that the reader will gain a flavor of this fascinating area of medicine. At the beginning of the twentieth century, Garrod introduced the concept of ‘chemical individuality’, leading in turn to the concept of the inborn error of metabolism (IEM). Beadle and Tatum later developed the idea that metabolic processes, whether in humans or any other organism, proceed by steps. They proposed that each step was controlled by a particular enzyme and that this, in turn, was the product of a particular gene. This was referred to as the one gene–one enzyme (or protein) concept.

Inborn Errors of Metabolism

In excess of 200 IEMs are known that can be grouped by either the metabolite, metabolic pathway, function of the enzyme, or cellular organelle involved (Table 11.1). Most follow autosomal recessive or X-linked recessive inheritance, with only a few being autosomal dominant. This is because the defective protein in most cases is a diffusible enzyme, and there is usually sufficient residual activity in the heterozygous state (loss-of-function, see p. 26) for the enzyme to function normally in most situations. If, however, the reaction catalysed by an enzyme is rate limiting (haploinsufficiency, see p. 26) or the gene product is part of a multimeric complex (dominant-negative, see p. 26), the disorder can manifest in the heterozygous state and follow dominant inheritance (p. 109).

Disorders of Amino Acid Metabolism

There are a number of disorders of amino acid metabolism, the best known of which is phenylketonuria.

Treatment of PKU

An obvious method of treating children with PKU would be to replace the missing enzyme, but this is not simply achieved (p. 349). Bickel, just 1 year after the enzyme deficiency had been identified, suggested that PKU could be treated by removal of phenylalanine from the diet and this has proved effective. If PKU is detected early enough in infancy, intellectual impairment can be prevented by giving a phenylalanine restricted diet. Phenylalanine is an essential amino acid and therefore cannot be removed entirely from the diet. By monitoring the level of phenylalanine in the blood, it is possible to supply sufficient amounts to meet normal requirements but avoiding toxic levels, resulting in mental retardation. After brain development is complete, dietary restriction can be relaxed—from adolescence onward.

The intellectual impairment seen in children with phenylketonuria is likely due to toxic levels of phenylalanine, and/or its metabolites, rather than a deficiency of tyrosine, of which adequate amounts are present in a normal diet. Both prenatal and postnatal factors may be responsible for developmental delay in untreated PKU.

Alkaptonuria

Alkaptonuria was the original autosomal recessive IEM described by Garrod. Here there is a block in the breakdown of homogentisic acid, a metabolite of tyrosine, because of a deficiency of the enzyme homogentisic acid oxidase (see Figure 11.1). As a consequence, homogentisic acid accumulates and is excreted in the urine, which then darkens on exposure to air. Dark pigment is also deposited in certain tissues, such as the ear wax, cartilage, and joints, where it is known as ochronosis, which in joints can lead to arthritis later in life.

Oculocutaneous Albinism

Oculocutaneous albinism (OCA) is an autosomal recessive disorder resulting from a deficiency of the enzyme tyrosinase, which is necessary for the formation of melanin from tyrosine (see Figure 11.1). In OCA there is a lack of pigment in the skin, hair, iris, and ocular fundus (Figure 11.3), and the lack of eye pigment results in poor visual acuity and uncontrolled pendular eye movements—nystagmus. Reduced fundal pigmentation leads to underdevelopment of part of retina for fine vision—the fovea—and abnormal projection of the visual pathways to the optic cortex.

Urea Cycle Disorders

The urea cycle is a five-step metabolic pathway that takes place primarily in liver cells for the removal of waste nitrogen from the amino groups of amino acids arising from the normal turnover of protein. It converts two molecules of ammonia and one of bicarbonate into urea (Figure 11.4). Deficiencies of enzymes in the urea cycle result in intolerance to protein from the accumulation of ammonia in the body—hyperammonemia. Increased ammonia levels are toxic to the central nervous system and can lead to coma and, with some untreated urea cycle disorders, death. They are collectively and individually rare and, with the exception of X-linked ornithine transcarbamylase deficiency, inherited as autosomal recessive traits.

Disorders of Carbohydrate Metabolism

The inborn errors of carbohydrate metabolism can be considered in two main groups: disorders of monosaccharide metabolism and the glycogen storage disorders.

Disorders of Monosaccharide Metabolism

Two examples of disorders of monosaccharide metabolism are galactosemia and hereditary fructose intolerance.

Glycogen Storage Diseases

Glycogen is the form in which the sugar glucose is stored in muscle and liver as a polymer, acting as a reserve energy source. In the glycogen storage diseases (GSDs) glycogen accumulates in excessive amounts in skeletal muscle, cardiac muscle, and/or liver because of a variety of inborn errors of the enzymes involved in synthesis and degradation of glycogen. In addition, because of the metabolic block, glycogen is unavailable as a normal glucose source. This can result in hypoglycemia, impairment of liver function and neurological abnormalities.

In each of the six major types of GSD, there is a specific enzyme defect involving one of the steps in the metabolic pathways of glycogen synthesis or degradation. The various types can be grouped according to whether they affect primarily the liver or muscle. All six types are inherited as autosomal recessive disorders, although there are variants of the hepatic phosphorylase that are X-linked.

Glycogen Storage Diseases that Primarily Affect Liver

Disorders of Steroid Metabolism

The disorders of steroid metabolism include a number of autosomal recessive inborn errors of the biosynthetic pathways of cortisol. Virilization of a female fetus may occur together with salt loss in infants of either sex from a deficiency of the hormone aldosterone. In addition, defects of the androgen receptor result in lack of virilization of chromosomally male individuals (Figure 11.5).

Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)

The diagnosis of congenital adrenal hyperplasia (CAH) should be considered in any newborn female infant presenting with virilization of the external genitalia, because this is the most common cause of ambiguous genitalia in female newborns (p. 288) (Figure 11.6). 21-Hydroxylase deficiency accounts for more than 90% of cases. Approximately 25% have the salt-losing form, presenting in the second or third week of life with circulatory collapse, hyponatremia, and hyperkalemia. Less commonly, CAH is a result of deficiency of the enzymes 11β-hydroxylase or 3β-dehydrogenase, and very rarely occurs as a result of deficiencies of enzymes 17α-hydroxylase and 17,20-lyase. Desmolase deficiency is very rare, with all pathways blocked, causing a reversed phenotype of ambiguous genitalia in males, and severe addisonian crises. Males with the rare 5α-reductase deficiency are significantly under-masculinized but do not suffer other metabolic problems and are likely to be raised as females. At puberty, however, the surge in androgen production is sufficient to stimulate growth of the phallus, making gender identity and assignment problematic.

Affected females with classic CAH are virilized from accumulation of the adrenocortical steroids proximal to the enzyme block in the steroid biosynthetic pathway, many of which have testosterone-like activity (see Figure 11.5). However, they have normal müllerian-derived internal organs. The possibility of CAH should not be forgotten, of course, in male infants presenting with circulatory collapse in the first few weeks of life.

Affected infants, in addition to requiring urgent correct assignment of gender, are treated with replacement cortisol, along with fludrocortisone if they have the salt-losing form. Virilized females may require plastic surgery later. Steroid replacement is lifelong and should be increased during intercurrent illness or stress, such as surgery. Menarche in girls with salt-losing CAH is late, menstruation irregular, and they are subfertile.

Androgen Insensitivity Syndrome

Individuals with the androgen insensitivity syndrome have female external genitalia and undergo breast development in puberty (p. 288). They classically present either with primary amenorrhea or with an inguinal hernia containing a gonad that turns out to be a testis. Inguinal hernia is uncommon in girls and if present, especially if bilateral, androgen insensitivity syndrome should be considered. There is often scanty secondary sexual hair and investigation of the internal genitalia reveals an absent uterus and fallopian tubes with a blind-ending vagina. Chromosome analysis reveals a normal male karyotype, 46,XY.

Androgen production by the testes is normal but androgen does not bind normally because of an abnormal androgen receptor (see Figure 11.5)—the androgen receptor gene on the X chromosome is mutated. This can be functionally assayed in skin fibroblasts. Some individuals have incomplete or partial androgen insensitivity, and under-virilization is variable. Affected subjects may have a female sexual orientation and are sterile. Testes must be removed because of an increased malignancy risk, and estrogen given for secondary sexual development and prevention of long-term osteoporosis.

Disorders of Lipid Metabolism

Familial hypercholesterolemia is the most common autosomal dominant single-gene disorder in Western society and is associated with high morbidity and mortality rates through premature coronary artery disease (p. 241).

Familial Hypercholesterolemia

Persons with familial hypercholesterolemia (FH) have raised cholesterol levels with a significant risk of developing early coronary artery disease (p. 241). They can present in childhood or adolescence with subcutaneous deposition of lipid, known as xanthomata (Figure 11.7). Starting with families who presented with early coronary artery disease, Brown and Goldstein unraveled the biology of the low-density lipoprotein (LDL) receptor (p. 241) and the pathological basis of FH.

image

FIGURE 11.7 Legs of a person homozygous for familial hypercholesterolemia, showing multiple xanthomata.

(Courtesy Dr. E. Wraith, Royal Manchester Children’s Hospital, Manchester, UK.)

Cells normally derive cholesterol from either endogenous synthesis or dietary uptake from LDL receptors on the cell surface. Intracellular cholesterol levels are maintained by a feedback system, with free cholesterol inhibiting LDL receptor synthesis as well as reducing the level of de novo endogenous synthesis.

High cholesterol levels in FH are due to deficient or defective function of the LDL receptors leading to increased levels of endogenous cholesterol synthesis. Four main classes of mutation in the LDL receptor have been identified: (1) reduced or defective biosynthesis of the receptor; (2) reduced or defective transport of the receptor from the endoplasmic reticulum to the Golgi apparatus; (3) abnormal binding of LDL by the receptor; and (4) abnormal internalization of LDL by the receptor (Figure 11.8). Specific mutations are more prevalent in certain ethnic groups because of founder effects (p. 133).

image

FIGURE 11.8 Stages in cholesterol biosynthesis and in the metabolism of low-density lipoprotein (LDL) receptors, indicating the types of mutation in familial hypercholesterolemia.

(Adapted from Brown MS, Goldstein JL 1986 A receptor-mediated pathway for cholesterol homeostasis. Science 232:34–47.)

The mainstay of management is dietary restriction of cholesterol intake and drug treatment with ‘statins’ that reduce the endogenous synthesis of cholesterol by inhibiting the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (CoA) reductase. Cholesterol levels in affected families are variable and lipid assays do not necessarily identify those with mutations. There is therefore interest in the introduction of widespread genetic testing, though most mutations are missense, which may pose problems of interpretation.

Lysosomal Storage Disorders

In addition to the IEMs in which an enzyme defect leads to deficiency of an essential metabolite and accumulation of intermediate metabolic precursors, there are a number of disorders in which deficiency of a lysosomal enzyme involved in the degradation of complex macromolecules leads to their accumulation. This accumulation occurs because macromolecules are normally in a constant state of flux, with a delicate balance between their rates of synthesis and breakdown. Children born with lysosomal storage diseases are usually normal initially but with the passage of time commence a downhill course of variable duration owing to the accumulation of one or more of a variety or type of macromolecules.

Mucopolysaccharidoses

Children with one of the mucopolysaccharidoses (MPSs) present with skeletal, vascular, or central nervous system findings along with coarsening of the facial features. These features are due to progressive accumulation of sulfated polysaccharides (also known as glycosaminoglycans) caused by defective degradation of the carbohydrate side-chain of acid mucopolysaccharide.

Six different MPSs are recognized, based on clinical and genetic differences. Each specific MPS type has a characteristic pattern of excretion in the urine of the glycosaminoglycans, dermatan, heparan, keratan, and chondroitin sulfate. Subsequent biochemical investigation has revealed the various types to be due to deficiency of different individual enzymes. All but Hunter syndrome, which is X-linked, are autosomal recessive disorders.

Treatment of the MPSs

Treatment of these disorders by enzyme replacement has proved difficult in practice (p. 349). However, bone marrow transplantation has been attempted with varying success, biochemically, and clinically in relation to the skeletal and cerebral features.

Sphingolipidoses (Lipid Storage Diseases)

In the sphingolipidoses, there is an inability to degrade sphingolipid, resulting in the progressive deposition of lipid or glycolipid, primarily in the brain, liver, and spleen. Central nervous system involvement results in progressive mental deterioration, often with seizures, leading to death in childhood. There are at least 10 different types, with specific enzyme deficiencies, Tay-Sachs, Gaucher, and Niemann-Pick diseases being the most common.

Gaucher Disease

This is the most common sphingolipidosis and, as with Tay-Sachs, is relatively more frequent among Ashkenazi Jews. There are two main types based on the age of onset.

Type I, with adult onset, is the more common form and presents with febrile episodes, pain in limbs, joints, or trunk, and a tendency to pathological fractures. Clinical examination usually reveals hepatosplenomegaly and investigations show mild anemia and radiological changes in the vertebrae and proximal femora. The central nervous system is spared.

In type II, infantile Gaucher disease, central nervous system involvement is a major feature and presents age 3 to 6 months with failure to thrive and hepatosplenomegaly. By 6 months, developmental regression and neurological deterioration occur with spasticity and seizures. Recurrent pulmonary infections cause death in the second year.

The diagnosis is confirmed by reduced activity of the enzyme glucosylceramide β-glucosidase in white blood cells or cultured fibroblasts.

Treatment in type 1 involves symptomatic analgesia, and sometimes splenectomy to prevent premature sequestration of red blood cells (hypersplenism). Initial attempts to treat adults by enzyme replacement therapy met with little success because of difficulty in obtaining sufficient quantities of enzyme and in targeting the appropriate sites. However, modification of β-glucosidase by the addition of mannose 6-phosphate, which targets the enzyme to macrophage lysosomes, has led to dramatic alleviation of symptoms and regression of organomegaly. The treatment is expensive, and regimens using lower doses and alternative methods to target the enzyme may be more rational.

Disorders of Purine/Pyrimidine Metabolism

Gout is the classic disorder of abnormal purine metabolism. Joint pain, swelling, and tenderness are a result of the inflammatory response of the body to deposits of crystals of a salt of uric acid. In fact, only a minority of persons with gout have an IEM. The cause in most instances results from a combination of genetic and environmental factors; however, it is always important to consider disorders that can result in an increased turnover of purines (e.g., a malignancy such as leukemia) or reduced secretion of the metabolites (e.g., renal impairment) as a possible underlying precipitating cause.

Disorders of Porphyrin Metabolism

There are several different disorders of porphyrin metabolism that are from a deficiency of enzymes in the biosynthetic pathway of the iron-containing group in hemoglobin—heme (p. 155). They all follow autosomal dominant inheritance, with the exception of autosomal recessive congenital erythropoietic porphyria. This is because the enzymes are rate limiting (p. 26), so that haploinsufficiency results in clinical disease.

The different types of porphyria are variably associated with neurological or visceral involvement and cutaneous photosensitivity from an accumulation of the different porphyrin precursors in those organs. The porphyrias are divided into two types depending on whether the excess production of porphyrins occurs predominantly in the liver or in the erythropoietic system.

Hepatic Porphyrias

These include acute intermittent porphyria, hereditary co-proporphyria, and porphyria variegata.

Porphyria Variegata

People with this form of porphyria, particularly prevalent in South African Afrikaans (p. 109), have variable skin photosensitivity with neurological and visceral features that can also be triggered by drugs. Increased fecal excretion of the porphyrin precursors protoporphyrin and co-proporphyrin can be demonstrated and the disorder has been shown to be due to deficiency of the enzyme protoporphyrinogen oxidase.

Organic-Acid Disorders

Children with one of the organic-acid disorders present with periodic episodes of poor feeding, vomiting, and lethargy in association with a severe metabolic acidosis, low white cell (neutropenia) and platelet (thrombocytopenia) counts, low blood sugar (hypoglycemia), and high blood ammonia levels (hyperammonemia). These episodes are often precipitated by intercurrent illness or increased protein intake, and after such an episode affected children can lose developmental skills. Analysis of blood from children at the time of these episodes reveals high levels of glycine (hyperglycinemia). It was subsequently found that the acidosis in these episodes was due to increased levels of the organic acids, either propionic or methylmalonic acid.

The two autosomal recessive organic-acid disorders methylmalonic acidemia and propionic acidemia are caused by deficiency of the enzymes methylmalonyl-CoA mutase and propionyl-CoA carboxylase, respectively. The enzyme deficiency results in accumulation of the toxic organic-acid metabolites derived from deamination of certain amino acids, specific long-chain fatty acids, and cholesterol side chains. Therapy for the acute episode involves the treatment of any infection, fluid replacement, correction of the metabolic acidosis, and cessation of protein intake. Long-term prophylactic treatment involves restriction of protein intake and rapid recognition and management of any intercurrent illness. A proportion of individuals affected with propionic acidemia are responsive to biotin, whereas some with methylmalonic acidemia are sensitive to vitamin B12.

Disorders of Copper Metabolism

There are two inborn errors of copper metabolism: Menkes disease and Wilson disease.

Peroxisomal Disorders

The peroxisomes are subcellular organelles bound by a single trilayer lipid membrane present in all cells; they are especially abundant in liver and renal parenchymal cells. The organelle matrix contains more than 40 enzymes that carry out a number of reactions involved in fatty-acid oxidation and cholesterol biosynthesis interacting with metabolic pathways outside the peroxisomes. The enzymes of the peroxisomal matrix are synthesized on the polyribosomes, enter the cytosol and are transferred into the peroxisomes.

There are two main categories of peroxisomal disorder: disorders of peroxisome biogenesis, such as Zellweger syndrome, in which there are severely reduced numbers of peroxisomes in all cells, and single isolated peroxisomal enzyme deficiencies, such as X-linked adrenoleukodystrophy.

Zellweger Syndrome

Newborn infants with Zellweger syndrome present with hypotonia and weakness and have mildly dysmorphic facial features (Figure 11.10), consisting of a prominent forehead and a large anterior fontanelle (‘soft spot’). They may also have cataracts and an enlarged liver. They generally go on to have fits with developmental regression and usually die by 1 year of age. Investigations can reveal renal cysts and abnormal calcification in the cartilaginous growing ends of the long bones (Figure 11.11). There is a range of severity of this disorder, with different clinical diagnoses being given to the less severe types. The diagnosis can be confirmed by raised levels of plasma long-chain fatty acids. It is genetically heterogeneous, due to any one of several genes crucial to peroxisome biogenesis.

It is unusual for IEMs to give rise to a dysmorphic syndrome (p. 249), but another is Smith-Lemli-Opitz syndrome, an inborn error of cholesterol biosynthesis from a mutation in the sterol delta-7-reductase (DHCR7) gene.

Disorders Affecting Mitochondrial Function

Mitochondrial disease was first identified in 1962 in a patient whose mitochondria showed structural abnormalities and loss of coupling between oxidation and phosphorylation, although it was not until 20 years later that the relevance of mutated mitochondrial DNA (mtDNA) to human disease began to be appreciated. The small circular double-stranded mtDNA (see Figure 2.7, p. 18) contains genes coding for ribosomal RNA (rRNA) production and various transfer RNAs (tRNA) required for mitochondrial protein biosynthesis, as well as some of the proteins involved in electron transport. There are 5523 codons and a total of 37 gene products. Guanine and cytosine nucleotides are asymmetrically distributed between the two mtDNA strands—the guanine-rich strand being called the heavy (H) strand and the cytosine-rich the light (L) strand. Replication and transcription is controlled by a 1122-bp sequence of mtDNA known as the displacement loop (D-loop). Oxidative phosphorylation (OXPHOS) is the biochemical process responsible for generating much of the ATP required for cellular energy. The process is mediated by five intramitochondrial enzyme complexes, referred to as complexes I–V, and the mtDNA encodes 13 OXPHOS subunits, 22 tRNAs, and 2 rRNAs.

The ‘complexes’ are aptly named. Analysis of complex I, for example, has revealed approximately 41 different subunits, of which 7 are polypeptides encoded by mtDNA genes known as ND1, ND2, ND3, NDL4, ND4, ND4L, ND5, and ND6, with the remaining 34 subunits encoded by nuclear DNA genes. Complex V comprises 12 or 13 subunits, of which two, ATPase 6 and 8, are encoded by mtDNA. Maximal activity of complex V appears to require tight linking with cardiolipin (see Barth syndrome, p. 182), encoded by nuclear DNA.

Because most mitochondrial proteins, including subunits involved in electron transport, are encoded by nuclear genes, these most often follow autosomal recessive inheritance. As with other metabolic autosomal recessive diseases, disorders resulting from mutations in these genes tend to breed true. However, the disorders resulting from mutations in mtDNA are extremely variable owing to the phenomenon of heteroplasmy (see Figure 7.30, p. 126). The clinical features are mainly a combination of neurological signs—encephalopathy, dementia, ataxia, dystonia, neuropathy, and seizures—and myopathic signs—hypotonia, weakness, and cardiomyopathy with conduction defects. Other symptoms and signs may include deafness, diabetes mellitus, retinal pigmentation, and acidosis may occur. The clinical manifestations are so variable that a mitochondrial cytopathy should be considered as a possibility at any age when the presenting illness has a neurological or myopathic component. Several distinct clinical entities have been determined and, although some of them overlap considerably, there is a degree of genotype–phenotype correlation.

Disorders of Mitochondrial Fatty-Acid Oxidation

In the 1970s, the first reports appeared of patients with skeletal muscle weakness and abnormal muscle fatty-acid metabolism associated with decreased muscle carnitine. The carnitine cycle is a biochemical pathway required for the transport of long-chain fatty acids into the mitochondrial matrix, and those less than 10 carbons in length are then activated to form acyl-CoA esters. The carnitine cycle is one part of the pathway of mitochondrial b-oxidation that plays a major role in energy production, especially during periods of fasting. Carnitine deficiency is a secondary feature of the β-oxidation disorders, with the exception of the carnitine transport defect where it is primary, and this rare condition responds dramatically to carnitine replacement. The more common fatty-acid oxidation disorders are outlined.

Further Reading

Benson PF, Fensom AH. Genetic biochemical disorders. Oxford: Oxford University Press; 1985.

A good reference source for detailed basic further information on the inborn errors of metabolism.

Clarke JTR. A clinical guide to inherited metabolic diseases. Cambridge: Cambridge University Press; 1996.

A good basic text, problem based and clinically oriented.

Cohn RM, Roth KS. Metabolic disease: a guide to early recognition. Philadelphia: WB Saunders; 1983.

A useful text as it considers the inborn errors from their mode of presentation rather than starting from the diagnosis.

Garrod AE. Inborn errors of metabolism. Lancet. 1908;ii:1-7. 73–79, 142–148, 214–220

Reports of the first inborn errors of metabolism.

Nyhan WL, Ozand PT. Atlas of metabolic diseases. London: Chapman & Hall; 1998.

A detailed text but very readable and full of excellent illustrations and clinical images.

Rimoin DL, Connor JM, Pyeritz RE, Korf BR, editors. Principles and practice of medical genetics, 4th edn, Edinburgh: Churchill Livingstone, 2001.

The section on metabolic disorders includes 13 chapters covering in succinct detail the various groups of metabolic disorders.

Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited disease, 8 edn, New York: McGraw Hill, 2000.

A huge multi-author three-volume comprehensive detailed text on biochemical genetics with an exhaustive reference list and, with this edition, a CD-ROM.